| Wu, Heshui |
| Active, not recruiting | 3 | 408 | RoW | KN046, placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Pancreatic Ductal Adenocarcinoma | 04/24 | 08/24 | | |
NCT06361030: Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 40 | RoW | surufatinib combined with gemcitabine plus nab-paclitaxel | Wuhan Union Hospital, China | Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Ductal Adenocarcinoma, PDAC | 06/26 | 06/27 | | |
AK104-217, NCT05859750: A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 78 | RoW | AK104, Gemcitabine, Nab-Paclitaxel, Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate, Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin | Akeso | Pancreatic Cancer | 06/25 | 12/25 | | |
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations |
|
|
| Recruiting | 1/2 | 290 | RoW | GFH375 | Genfleet Therapeutics (Shanghai) Inc. | KRAS G12D Mutations, Advanced Solid Tumors | 07/28 | 12/28 | | |
NCT05911217: A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer |
|
|
| Recruiting | 1 | 20 | RoW | CT041 autologous CAR T-cell injection, Single Group Assignment | CARsgen Therapeutics Co., Ltd., Fudan University | Pancreatic Cancer | 12/26 | 12/26 | | |
